OAB and Incontinence

R. Corey O'Connor, MD, discusses findings from a recent study published in Neurourology and Urodynamics.

Lunan Ji, MD, discusses a recent paper published in Urology that evaluated the quality of patient education materials on YouTube related to overactive bladder.

“Although IPSS may not be familiar to gynecologists and urogynecologists, this minimally invasive self-reported questionnaire is useful in counseling preoperative pelvic organ prolapse patients with OAB symptoms," researchers write.

“The present study clearly shows that test duration and reprogramming during the test phase increases the number of patients that benefit in the long term from sacral neuromodulation,” researchers wrote.

Outcomes for patients using telemedicine were equal, and patients were as satisfied as those who had office-based postoperative visits.

Smoking had a particularly strong impact on OAB risk in younger individuals.

Gopal H. Badlani, MD, discusses the recently presented long-term safety profile of the β-3 adrenoceptor agonist vibegron.

Jeffrey P. Weiss, MD, PhD, discusses how he defines nocturia, how to separate the symptom from overactive bladder, and how he conducts patient work-ups for nocturia

Data from a pivotal trial showed the eCoin Peripheral Neurostimulator led to a clinically significant improvement in urgency urinary incontinence.

Beta 3-adrenergic receptor agonist’s benefits observed at 52 weeks, investigators report.

The OASIS study is examining the RENOVA iStim implantable tibial neuromodulation system for the treatment of women with overactive bladder.

InterStim Micro treats patients with overactive bladder, fecal incontinence, and non-obstructive urinary retention by delivering sacral neuromodulation therapy.

Feasibility study results indicate the nonimplanted, intravaginal device is safe and comfortable.

Treatment with litoxetine, an investigational oral selective serotonin reuptake inhibitor, led to nearly 22% of patients becoming continent.

The reduction in urinary urgency incontinence episodes observed was “quite significant,” an investigator said.

Urologists must differentiate between bladder outlet obstruction and pure OAB in male patients, according to Osvaldo F. Padron, MD.

An investigational wireless, implantable tibial nerve stimulator is safe and provided improvement in overactive bladder symptoms over 3 years of follow-up.

Mirabegron (Myrbetriq) is effective and well tolerated in patients age 65 or older with overactive bladder, results of a randomized, placebo-controlled study show.

A recent study found that sacral neuromodulation monotherapy was efficacious as a third-line treatment.

Nocturia appears to be highly prevalent in the United States, with almost 30% of all women reporting significant nocturia, according to new data reported at the AUA annual meeting in San Francisco.

 Waking up at night to urinate is by far the most bothersome lower urinary tract symptom. 

The therapeutic efficacy of sacral neuromodulation was not affected by non-head magnetic resonance imaging scans in a recent study.

Over half of patients stop intradetrusor botulinum toxin injections within 10 years, mostly due to lack of clinical efficacy, researchers say.

In this interview, J. Quentin Clemens, MD, discusses the work being done by the MAPP (Multidisciplinary Approach to Chronic Pelvic Pain) Research Network and LURN (Symptoms of Lower Urinary Tract Dysfunction Research Network) research initiatives.

“The results suggest that this compound has rapid efficacy and a favorable safety profile in patients with nocturia due to nocturnal polyuria,” says researcher Diane Newman, DNP.